Akebia Therapeutics, Inc. revised earnings guidance for the full year 2022. For the year, the company is increasing its net product revenue guidance for Auryxia to $170 million to $175 million for fiscal year 2022, raising both the top and bottom end of the guidance range by $5 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.34 USD | +0.75% | -1.47% | +8.06% |
Apr. 23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
Apr. 16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.06% | 278M | |
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |
- Stock Market
- Equities
- AKBA Stock
- News Akebia Therapeutics, Inc.
- Akebia Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2022